Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Reexamination Certificate
2006-04-18
2006-04-18
Yaen, Christopher (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
C530S327000, C514S002600
Reexamination Certificate
active
07030212
ABSTRACT:
A tumor antigen that comprises, as an active ingredient, a product of the Wilms', tumor suppressor gene WT1 or a peptide composed of 7–30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising said antigen.
REFERENCES:
patent: 5622835 (1997-04-01), Herlyn et al.
patent: 5840839 (1998-11-01), Wang et al.
patent: 6034235 (2000-03-01), Sugiyama et al.
patent: 6207880 (2001-03-01), Kossmann et al.
patent: 2003/0039635 (2003-02-01), Gaiger et al.
patent: 2003/0072767 (2003-04-01), Gaiger et al.
patent: 2003/0082196 (2003-05-01), Gaiger et al.
patent: 2003/0092656 (2003-05-01), Sugiyama
patent: 2003/0095971 (2003-05-01), Gaiger et al.
patent: 2003/0198622 (2003-10-01), Gaiger et al.
patent: 2003/0215458 (2003-11-01), Gaiger et al.
patent: 2003/0235557 (2003-12-01), Gaiger et al.
patent: 2004/0018204 (2004-01-01), Gaiger et al.
patent: 2004/0097703 (2004-05-01), Sugiyama
patent: 2004/0126362 (2004-07-01), Gaiger et al.
patent: 2004/0247609 (2004-12-01), Sugiyama
patent: 2005/0002951 (2005-01-01), Sugiyama et al.
patent: 1 004 319 (1998-07-01), None
patent: 1 074 267 (2000-07-01), None
patent: 1 103 564 (2001-05-01), None
patent: 61-22018 (1986-01-01), None
patent: 9-104629 (1997-04-01), None
patent: 2001-89389 (2001-04-01), None
patent: 91/07509 (1991-05-01), None
patent: WO 95/16464 (1995-06-01), None
patent: 95/29995 (1995-11-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 96/38176 (1996-12-01), None
patent: WO 99/44634 (1999-09-01), None
patent: WO 00/06602 (2000-02-01), None
patent: WO 00/18795 (2000-04-01), None
patent: WO 00/26249 (2000-05-01), None
patent: WO 00/41463 (2000-07-01), None
patent: WO 00/44349 (2000-08-01), None
patent: WO 01/62920 (2001-08-01), None
patent: WO 02/79253 (2002-10-01), None
patent: WO 03/106682 (2003-12-01), None
Wang et al (J. Biol. Chem. 1992; 267(31):21999-22002.
Yasukawa et al (Blood Nov. 1998; 92(10) part 1, Suppl. 1: Abstract #2541).
Gura (Science, v278, 1997, pp. 1041-1042).
Bellone et al (Immunology Today, v20 (10), 1999, pp. 457-461).
Gaiger et al. (Blood, vol. 96, No. 4, Aug. 2000, pp. 1480-1489).
Riott et al (Immunology, Fourth Edition, 1996, Mosby, p. 7.9-7.11).
Gaiger, A. et al., “WT1: A new leukemia and cancer antigen” #2802,Proceedings of the American Association for Cancer Research, vol. 40, Immunology/Preclinical and Clinical 7, p. 424, (Mar./1999).
Rammensee, Hans-Georg et al., “MHC ligands and peptide motifs: first listing”,Immunogenetics, 41, No. 4, Springer-Verlag 1995, pp. 178-228, (1995).
Melief, C. JM et al., “Potential immunogenicity of oncogene and tumor suppressor gene products”,Current Opinion in Immunology 1993, vol. 5, Current Biology Ltd ISSN 0952-7915, pp. 709-713, (1993).
Pardoll, Drew M, New strategies for enhancing the immunogenicity of tumors,Current Opinion in Immunology 1993, vol. 5, Current Biology Ltd ISSN 0952-7915, pp. 719-725, (1993).
Buckler, Alan J. et al., “Isolation, Characterization, and Expression of the Murine Wilms' Tumor Gene (WT1) During Kidney Development”,Molecular and Cellular Biology, vol 11, No. 3, 1991, American Society for Microbiology, pp. 1707-1712, (Mar. 1991).
Patent Family Information of Attached Reference WO 00/18795.
Patent Family Information of Attached Reference WO 00/26249.
B. Palermo, et al., “Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: a Qualitative Analysis”, Melanoma Research, 2002, 12, pp. 491-498.
L. Gao, et al., “Selective Elimination of Leukemic CD34+Progenitor Cells by Cytotoxic T Lymphocytes Specific for WT1”, Blood, Apr. 1, 2000, vol. 95, No. 7, pp. 2198-2203.
N. Renkvist, et al., “A Listing of Human Tumor Antigens Recognized by T Cells”, Cancer Immunol. Immunother, 2001, 50: pp. 3-15.
M. Gessler, et al., “Homozygous Deletion in Wilms Tumours of a Zinc-Finger Gene Identified by Chromosome”, Nature, vol. 343, Feb. 22, 1990, pp. 774-778.
A. Tsuboi, et al., “Cytotoxic T-Lymphocyte Responses Elicited to Wilms' Tumor Gene WT1 Product by DNA Vaccination”, Journal of Clinical Immunology, vol. 20, No. 3, 2000, pp. 195-202.
A. Gaiger, et al., “Immunity of WT1 in the Animal Model and in Patients with Acute Myeloid Leukemia”, Aug. 15, 2000, vol. 96, No. 4, pp. 1480-1489.
W. Barclay, et al., “Effects of Oil-Treated Mycobacterial Cell Walls of the Organs of Mice”, Journal of Bacteriology, No. 1967, pp. 1736-1745.
M. Yamawaki, et al., “Antitumor Activity of Squalene-Treated Cell-Wall Skeleton of Nocardia Rubra in Mice”, Gann, vol. 69, No. 5, pp. 619-626.
E. Ribi, et al., “Factors Influencing Protection Against Experimental Tuberculosis in Mice by Heat-Stable Cell Wall Vaccines”, Journal of Bacteriology, Oct. 1966, vol. 92, No. 4, pp. 869-879.
H. Sugiyama, “Wilms' Tumor Gene WT1: Its Oncogenic Function and Clinical Application”, International Journal of Hematology, vol. 73, 2001, pp. 177-187.
R. Lin, et al., “Present Status of the Use of Cytokines as Adjuvants with Vaccines to Protect Against infectious Diseases”, Clin. Infect. Dis., vol. 21, No. 6, 1995, pp. 1439-1449.
Y. Tanio, Partial Englis Translation of Japanese Journal of Cancer and Chemotherapy, vol. 7, No. 9, pp. 1710-1718, 1980.
T. Azuma, et al., “Identification of a Novel WT1-Derived Peptide Which Induces Human Leucocyte Antigen-A24-Restricted Anti-Leukaemia Cytotoxic T Lymphocytes”, British Journal of Haematology, 2002, 116, pp. 601-603.
The 31stAnnual Meeting of the Japanese Society for Immunology, pp. 160, 2-C-W11-8-P Abstract enclosed.
S. Rosenberg, et al., “A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens”, Immunity, vol. 10, pp. 281-287, Mar. 1999.
A. Bakker, et al., Melanocyte Lineage-Specific Antigen gp100 is Recognized by Melanoma-Derived Tumor-Infiltrating Lymphocytes, The Journal of Experimental Medicine, vol. 179, Mar. 1994, pp. 1005-1009.
Y. Kawakami, et al., “Cloning of the Gene Coding for a Shared Human Melanoma Antigen Recognized by Autologous T Cells Infiltrating into Tumor”, Proc. Natl. Acad. Sci., USA, vol. 91, pp. 3515-3519, Apr. 1994.
V. Brichard, et al., “The Tyrosinase Gene Codes for an Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas”, Journal of Experimental Medicine, vol. 178, Aug. 1993, pp. 489-495.
B. Fisk, et al., “Identification of an Immunodominant Peptide of HER-2
eu Protooncogene Recognized by Ovarian Tumor-specific Cytotoxic T Lymphocyte Lines”, Journal of Experimental Medicine, vol. 181, Jun. 1995, pp. 2109-2117.
K. Tsang, et al., “Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes from Patients Immunized with Recombinant Vaccinia-CEA Vaccine”, Journal of the National Cancer Institute, vol. 87, No. 13, Jul. 5, 1995, pp. 982-990.
P. Correale, et al., “In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived from Prostate-Specific Antigen”, Journal of the National Cancer Institute, vol. 89, No. 4, Feb. 19, 1997.
K. Call, et al., “Isolation and Characterization of a Zinc Finger Polypeptide Gene at the Human Chromosome 11 Wilms' Tumor Locus”, Cell, vol. 60, Feb. 9, 1990, pp. 509-520.
N. Nanda, et al., “Induction of Anti-Self-Immunity to Cure Cancer”, Cell, vol. 82, Jul. 14, 1995, pp. 13-17.
C. Melief, et al., “T-Cell Immunotherapy of Tumors by Adoptive Transfer of Cytotoxic T Lymphocytes and by Vaccination wit Minimal Essential Epitopes”, Immunological Reviews, 1995, No. 146, pp. 167-177.
Y. Oka, et al., Hematology Frontier, 2000, vol. 10, No. 8, pp. 1017-1023, “3. Men'eki Ryoho 2) WT1 o Hyotekki to shita Hakketsubyo ni Taisuru Tokuiteki Men'eki Ryoho”.
Y. Oka, et al., “Induction of WT1 (Wilms' Tumor G
Oka Yoshihiro
Sugiyama Haruo
Haruo Sugiyama
Yaen Christopher
LandOfFree
Tumor antigen based on products of the tumor suppressor gene... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor antigen based on products of the tumor suppressor gene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor antigen based on products of the tumor suppressor gene... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3594514